<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338375</url>
  </required_header>
  <id_info>
    <org_study_id>2012-10-078</org_study_id>
    <nct_id>NCT02338375</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product</brief_title>
  <acronym>Cartistem</acronym>
  <official_title>Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of adding allogenic
      umbilical cord blood-derived stem cell product(Cartistem®) on currently standard treatment of
      arthroscopic curettage and microfracture for osteochondral lesion of talus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      same as above
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12, Week 24, Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by 100-mm VAS(Visual Analogue Scale)</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12, Week 24, Week 48</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by ICRS arthroscopic scale for repair of articular cartilage</measure>
    <time_frame>Baseline, Week 4, Week 8, Week 12, Week 24, Week 48</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Osteochondral Lesion of Talus</condition>
  <arm_group>
    <arm_group_label>Cartistem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cartistem</intervention_name>
    <description>Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.</description>
    <arm_group_label>Cartistem</arm_group_label>
    <arm_group_label>standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-responder to conservative treatment for radiographically confirmed (by MRI)
             osteochondral lesion of talus with ankle pain and/or stiffness and less than 75 of the
             AOFAS score

          -  Age between 20 and 70 year-old

          -  Appropriate function of blood clot PT(INR) &lt; 1.5, APTT &lt;1.5×control

          -  Appropriate renal function Creatinine ≤ 2.0 ㎎/㎗, proteinuria less than trace with
             Dipstick urine test

          -  Appropriate hepatic function Bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L

          -  No evidence of autoimmue disorder As screening test anti-nuclear antibody and/or
             anti-thyroglobulin antibody, if positive rheumatologist referral needed to confirm
             diagnosis

          -  No surgery or radiotherapy for the same ankle joint within 6 weeks

          -  Female patients agreeing with maintenance of contraception during study period

          -  No ligament instability greater than grade II (Grade 0 : none, Grade Ⅰ: 0~5㎜, GradeⅡ:
             5~10㎜, Grade Ⅲ: &gt;10㎜) with physical exam

          -  Patients agreeing with participation in this study and signed on informed consent by
             their own will

        Exclusion Criteria:

          -  Degenerative ankle arthritis patients

          -  Patients with autoimmune disease

          -  Patients with infectious disease needed parenteral antibiotics

          -  Patients with myocardial infarction, congestive heart failure, other serious heart
             diseases or uncontrollable hypertion

          -  Patients with other serious medical illness

          -  Pregnancy or breast feeding patients

          -  Past history related with psychiatric illness or epilepsy

          -  Alcoholic abuse

          -  Heavy smoker

          -  Chronic inflammatory disease including rheumatoid arthritis

          -  Participants of other clinical trial within 4 weeks

          -  Patients treated with immunosuppressing agents such as Cyclosporin A or azathioprine
             within 6 weeks

          -  Unstable ankle joint(lesion site) greater than grade II at physical exam (Grade 0 :
             none, grade Ⅰ: 0~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: &gt;10㎜)

          -  Other inappropriate patients determined by the prinicipal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-Gu</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2015</study_first_posted>
  <last_update_submitted>January 11, 2015</last_update_submitted>
  <last_update_submitted_qc>January 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>ChulWon Ha</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

